FDA Peptide Reclassification 2026: What's Actually Happened (And What Hasn't)
Every clinic site says peptides are legal again. Here's what the FDA has actually done.
On February 27, 2026, HHS Secretary RFK Jr. announced that ~14 of 19 Category 2 peptides would return to Category 1, restoring compounding eligibility. As of March 28 — 29 days later — the FDA has not published any formal reclassification. The legal status of BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, and other Category 2 peptides is unchanged. This page will be updated within 24 hours of any formal FDA action.
What Was Announced
On February 27, 2026, during Joe Rogan Experience Episode #2461, HHS Secretary Robert F. Kennedy Jr. made three key statements about peptides:
First, that his team had reviewed the FDA’s 2023 decision to place 19 peptides in Category 2 and determined the agency lacked the required safety signal to justify the restrictions. Under Section 503A of the FD&C Act, the FDA can restrict compounding when a substance presents a “significant safety risk.” Kennedy’s argument is that most of these peptides had been compounded for years without documented safety signals.
Second, that approximately 14 of the 19 restricted peptides would be moved back to Category 1 — meaning licensed compounding pharmacies could legally prepare them again with a valid physician prescription.
Third, that this would happen “within a couple of weeks.”
What Has Actually Happened
As of March 28, 2026:
No Federal Register notice has been published regarding peptide reclassification.
No updated Category 2 list has appeared on FDA.gov.
No interim guidance has been issued to compounding pharmacies.
No official list of which specific peptides would return to Category 1 versus remain restricted has been released.
An HHS spokesperson, when contacted by NPR for their March 26 segment, did not provide a timeline for when reclassification would occur.
The legal status of all 19 Category 2 peptides remains exactly as it was on February 26, 2026 — the day before the announcement.
What the Reclassification Would Mean (When It Happens)
If and when the FDA formally moves peptides from Category 2 to Category 1, here’s what changes and what doesn’t:
What changes: Licensed 503A compounding pharmacies can legally prepare these peptides for individual patients with valid physician prescriptions. Licensed 503B outsourcing facilities can compound them in larger quantities. Compounding pharmacies would source pharmaceutical-grade APIs (active pharmaceutical ingredients) through regulated supply chains.
What does NOT change: These peptides would not become FDA-approved drugs. They would not have demonstrated safety and efficacy through clinical trials. They would not be available over the counter. They would still require a physician’s prescription. The evidence gaps PeptideExaminer has documented in every peptide profile would remain identical.
What this is NOT: FDA approval. OTC access. Scientific validation. Proof that these peptides work. A green light to buy from grey-market vendors.
Which Peptides Are Expected to Return
Based on Kennedy’s statements, industry analysis, and the strength of existing safety data, these 14 peptides are expected to move to Category 1:
| Peptide | Primary Research Area | Human Clinical Data |
|---|---|---|
| BPC-157 | Tissue repair, gut healing | Zero completed trials |
| Thymosin Alpha-1 | Immune modulation | Approved in 30+ countries (not US) |
| TB-500 (Tβ4 fragment) | Wound healing, recovery | Limited (full-length Tβ4 only) |
| AOD-9604 | Fat metabolism | Phase IIb (failed efficacy endpoint) |
| CJC-1295 | Growth hormone release | One published PK study |
| Ipamorelin | Growth hormone release | Limited Phase I/II |
| Selank | Anxiolytic, immune | Approved in Russia only |
| Semax | Nootropic, cognitive | Approved in Russia only |
| GHK-Cu (injectable) | Anti-aging, wound healing | Moderate (mostly topical) |
| KPV | Anti-inflammatory, gut | Zero human trials |
| MOTS-c | Mitochondrial, metabolic | Very limited |
| Epitalon | Telomerase activation | Minimal |
| Kisspeptin-10 | Reproductive hormones | Active clinical research |
| DSIP | Sleep regulation | Limited, dated |
Which Peptides Are Expected to Stay Restricted
Approximately five peptides are expected to remain in Category 2 due to stronger safety concerns:
| Peptide | Likely Reason for Continued Restriction |
|---|---|
| Melanotan II | Cardiovascular effects, melanoma risk concerns |
| LL-37 | Very limited human safety data |
| PEG-MGF | Insufficient human clinical data |
| GHRP-2 | Less favorable safety profile vs. alternatives |
| MK-677 (Ibutamoren) | PCAC voted against compounding (Dec 2024) |
This list is not confirmed. No official determination has been published.
The Grey Market Question
Kennedy explicitly acknowledged on the podcast that the Category 2 restrictions “created the grey market.” The logic is straightforward: when regulated compounding was banned, demand didn’t disappear — it moved to unregulated channels. Chinese peptide imports to the US roughly doubled to $328 million in the first three quarters of 2025.
The reclassification argument positions regulated compounding as the harm-reduction alternative to unregulated imports. This is a defensible public health argument. But it’s important to understand what reclassification does and doesn’t do to the grey market:
It creates a legal alternative — physician prescription + compounding pharmacy provides a regulated pathway that didn’t exist under Category 2.
It does not validate the grey market — grey-market vendors selling “research use only” peptides remain in the same legal position regardless of reclassification. The Intended Use Doctrine, ITC exclusion orders, and the SAFE Drugs Act all target the grey-market model independently of compounding eligibility.
It may accelerate grey-market decline — when a legal pathway exists, the justification for buying unregulated products weakens. This is already happening: Peptide Sciences shut down March 6, Amino Asylum was raided in June 2025, and 7+ vendors closed in 2025.
What to Do Right Now
Do not buy from grey-market vendors based on the reclassification announcement. The announcement doesn’t change grey-market legality at all. If anything, it signals that a legal alternative is coming — which makes the illegal pathway less defensible.
Do not assume your compounding pharmacy can already prepare these peptides. Until formal reclassification publishes, Category 2 restrictions are in effect. Pharmacies compounding these substances now are taking regulatory risk.
Find a physician who understands peptide therapy. When reclassification happens, you’ll need a prescription from a licensed provider. Establishing that relationship now means you’ll be ready when the regulatory pathway opens.
Be skeptical of clinic websites claiming peptides are “legal again.” They’re marketing to you. The formal action hasn’t happened yet. Ask them to show you the Federal Register notice. They can’t, because it doesn’t exist.
Read the actual evidence for any peptide you’re considering. Reclassification doesn’t change the science. Our peptide profiles provide evidence-rated assessments of what published research actually shows for each compound — not what influencers or clinics claim.
PeptideExaminer Will Update This Page
When the FDA formally publishes the reclassification, this page will be updated within 24 hours with:
- The complete official list of reclassified peptides
- Analysis of which stayed restricted and why
- Guidance on accessing peptides through compounding pharmacies
- Updated regulatory status in every affected peptide profile
- Assessment of implications for the grey market
Bookmark this page. We’ll have the independent analysis when it matters.
Joe Rogan Experience #2461 (February 27, 2026); NPR Health segment (March 26, 2026); Congress.gov H.R. 6509 (SAFE Drugs Act bill text); FDA.gov bulk drug substances list; PolitiFact peptide safety fact-check (March 6, 2026); Frier Levitt regulatory analysis; PeptideExaminer enforcement database.
PeptideExaminer — We don’t sell peptides. We tell you the truth about them.